Question · asked by 1 review
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy: Specific adverse events: haemorrhage
- Population
- women with recurrent or FIGO stage IVB cervical cancer
- Intervention
- Apatinib plus chemotherapy or chemotherapy/brachytherapy
- Comparison
- chemotherapy or chemotherapy/brachytherapy
- Outcome
- Specific adverse events: haemorrhage
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy Specific adverse events: haemorrhage ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer The review found no eligible studies for this question. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.